Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC

Rothschedl E
Record ID 32018000325
Authors' results and conclusions: CheckMate 214 study results show that the combination of nivolumab and ipilimumab provides a clinical benefit in previously untreated, intermediate- and poor-risk patients. However, the high rate of treatment-related adverse effects (AEs) needs to be taken into consideration. Moreover, data regarding AEs for intermediate- and poor-risk patients and, additionally, long-term efficacy and safety data of the combination therapy would be of interest.
Authors' recomendations: Since CheckMate 214 is the only phase III trial providing results of nivolumab plus ipilimumab in untreated patients with advanced RCC, more data is needed to evaluate this combination regimen as a first-line therapy.
Project Status: Completed
Year Published: 2018
URL for additional information:
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Therapeutics
  • Nivolumab
  • Carcinoma, Renal Cell
  • Pharmacology
  • Kidney Neoplasms
  • Drug Therapy, Combination
  • Ipilimumab
  • Quality of Life
  • Renal cell carcinoma
  • nivolumab
  • Opdivo®
  • ipilimumab
  • Yervoy®
  • first-line therapy
  • anti- PD-1 monoclonal antibody
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
Contact Email:
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.